ImmunoPrecise Antibodies Ltd. Files 6-K with Financial Updates
Ticker: HYFT · Form: 6-K · Filed: Mar 14, 2024 · CIK: 1715925
Sentiment: neutral
Topics: financial-update, sec-filing, assets
TL;DR
IPA filed a 6-K showing asset depreciation and carrying amounts as of Jan 31, 2024.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a 6-K report on March 14, 2024, detailing financial information for the period ending January 31, 2024. The filing includes data related to accumulated depreciation and amortization, net book value, and gross carrying amounts for various assets, including lab equipment and proprietary processes, across different reporting periods.
Why It Matters
This filing provides investors with updated financial data, offering insights into the company's asset values and depreciation schedules, which can impact profitability and asset management strategies.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) that provides updated financial data without announcing significant new events or changes.
Key Numbers
- 2024-01-31 — Reporting Period End Date (The latest date for which financial data is provided.)
- 2023-04-30 — Previous Reporting Period End Date (Provides comparative financial data.)
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- 20240131 (date) — Conformed period of report
- 20240314 (date) — Filing date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to provide updated financial information for ImmunoPrecise Antibodies Ltd. for the period ending January 31, 2024, including details on asset depreciation and carrying amounts.
What specific financial elements are detailed in the filing?
The filing details elements such as accumulated depreciation and amortization, net book value, and gross carrying amounts for lab equipment, proprietary processes, and buildings.
What are the reporting periods covered by the financial data?
The financial data covers periods ending January 31, 2024, April 30, 2023, and April 30, 2022, as well as interim periods like January 31, 2023.
Where is ImmunoPrecise Antibodies Ltd. based?
ImmunoPrecise Antibodies Ltd. is based in Vancouver, Canada, with a business address at 880 - 580 Hornby Street, Vancouver, BC V6C3B6.
What is the SIC code for ImmunoPrecise Antibodies Ltd.?
The Standard Industrial Classification (SIC) code for ImmunoPrecise Antibodies Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 278 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-03-14 08:00:35
Filing Documents
- ipa-20240131.htm (6-K) — 255KB
- ipa-ex99_1.htm (EX-99.1) — 546KB
- ipa-ex99_2.htm (EX-99.2) — 1981KB
- ipa-ex99_3.htm (EX-99.3) — 23KB
- ipa-ex99_4.htm (EX-99.4) — 21KB
- img36100363_0.jpg (GRAPHIC) — 9KB
- img37023884_0.jpg (GRAPHIC) — 9KB
- 0000950170-24-031153.txt ( ) — 12396KB
- ipa-20240131.xsd (EX-101.SCH) — 1824KB
- ipa-20240131_htm.xml (XML) — 3025KB
Management's Discussion and Analysis for the three and nine months ended January 31, 2024 and 2023
Management's Discussion and Analysis for the three and nine months ended January 31, 2024 and 2023 99.2 Condensed Interim Consolidated Financial Statements for the three and nine months ended January 31, 2024 and 2023 99.3 CEO Certification (pursuant to Canadian regulations) 99.4 CFO Certification (pursuant to Canadian regulations) 101.INS Inline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: March 14, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer